- Home
- DOCU vs PODD Comparison
DOCU vs PODD Comparison
Compare DOCU & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DOCU | PODD |
|---|---|---|
| Founded | 2003 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.0B | 10.2B |
| IPO Year | 2018 | 2007 |
Fundamental Metrics
Financial Performance| Metric | DOCU | PODD |
|---|---|---|
| Price | $84.98 | $149.15 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 20 | 26 |
| Target Price | $69.99 | ★ $167.17 |
| AVG Volume (30 Days) | ★ 2.4M | 1.3M |
| Earning Date | 12-03-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.80 | ★ 2.67 |
| Revenue | ★ $3,219,500,000.00 | $2,708,100,000.00 |
| Revenue This Year | $8.86 | $21.37 |
| Revenue Next Year | $7.96 | $13.57 |
| P/E Ratio | $105.19 | ★ $55.34 |
| Revenue Growth | 8.16 | ★ 30.73 |
| 52 Week Low | $40.16 | $126.40 |
| 52 Week High | $85.36 | $354.88 |
Technical Indicators
Market Signals| Indicator | DOCU | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 76.04 | 66.33 |
| Support Level | $42.89 | $139.67 |
| Resistance Level | N/A | $153.33 |
| Average True Range (ATR) | 2.84 | 4.07 |
| MACD | 1.19 | 1.79 |
| Stochastic Oscillator | 98.33 | 98.37 |
Price Performance
Historical ComparisonAbout DOCU DocuSign Inc.
Docusign offers Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its initial public offering in 2018.
About PODD Insulet Corporation
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.